Bain Capital-Backed Emcure Pharma Sets IPO Price Band At Rs 960–1,008 Apiece
Emcure Pharmaceuticals Ltd. has set a price band of Rs 960–1,008 per share for its upcoming initial public offering. The company seeks to raise up to Rs 1,952 crore through a fresh issue of Rs 800 crore and an offer for sale of 1.14 lakh crore equity shares.
The public issue of the Pune-based pharmaceutical company will open for subscription on July 3 and conclude on July 5. Bidding for the anchor portion will open for a day on July 2.
The minimum lot size for bidding will be 14 shares, with further bids to be made in multiples, according to the price band advertisement released by the company on Friday.
Among the selling shareholders in the offer for sale is BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital, that will offload 72.34 lakh shares.
Kotak Mahindra Capital Co., Axis Capital Ltd., Jefferies India Pvt. and JPMorgan India Pvt. are the book-running lead managers for the issue.
About Emcure Pharma
Emcure Pharma is engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
The company has more than 350 brands, five research and development centres, and 14 manufacturing facilities across India, as per information on its website. It sells in over 70 countries.
The net proceeds from the fresh issue will be used to repay debt and for general corporate purposes.
In its latest financials as of September 2023, the company reported a consolidated net profit of Rs 287 crore and revenue of Rs 3,219 crore. The company's total outstanding borrowings were Rs 2,013 crore.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
